Irradiated Donor Lymphocytes and Rituximab in Treating Patients With Relapsed or Refractory Lymphoproliferative Disease
Stopped early · Phase 1
Conditions studied: Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
In brief
RATIONALE: When irradiated lymphocytes from a donor are infused into the patient they may help the patient's immune system kill cancer cells. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Giving irradiated donor lymphocytes together with rituximab may kill more cancer cells. PURPOSE: This clinical trial is studying the side effects and how well giving irradiated donor lymphocytes together with rituximab works in treating patients with relapsed or refractory lymphoproliferative disease.
Key facts
- Study ID
- NCT00176475
- Run by
- University of Medicine and Dentistry of New Jersey
- People needed
- 2
- Starts
- 2005-01-01
- Expected to finish
- 2008-02-01
- Last updated by the study team
- 2013-09-17
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School — New Brunswick, New Jersey, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.